Entact Bio is developing a novel class of precision medicines that enhance the function of beneficial proteins. Launched by a founding team deeply rooted in deubiquitinase (DUB) biochemistry, chemical biology, disease biology, and small-molecule drug development, Entact has built its proprietary Encompass™ platform to create enhancement-targeting chimeric (ENTAC™) medicines. ENTACs leverage the natural ability of DUBs to regulate and enhance protein function. By harnessing the power of DUBs, Entact is expanding the universe of treatable diseases and creating new options for patients who are underserved by current therapeutic modalities.

Entact Bio

Entact Bio Appoints Michael Gutch, Ph.D., as Chief Operating Officer

Weekly Pharma & Life Science News Round-Up: 5th – 9th December 2022

Protein Enhancement Therapeutics Company Entact Bio Raises $81M in Series A Round | Inside Precision Medicine

Victoria Richon

Chief Executive Officer

Director, Biological Sciences

Director | Group Leader | Oncology

Associate Principal Scientist

Senior Scientist

Scientist

In-Vitro Assay Development and Screening Scientist (Contract)

In-Vitro Assay Development & Screening Services (Contract)

Director of In-Vitro Biology

Research Scientist / Sr. Principal Scientist

Sr. Market Analyst

Scientist /Sr. Scientist

Associate Scientist / Scientist

Assistant Scientist / Associate Scientist

Scientist II

Research Scientist

Scientific Associate II

Mechanistic Biology Co-op

Volunteer

Intern

SVP, Molecular Discovery

Director

Associate Director

Research Associate

Principal Scientist, Biological Sciences

Principal Scientist, Rare Disease

Postdoctoral Research Fellow

Senior postdoctoral research fellow

Senior Principal Scientist

Associate Principal Scientist, Pharmacology

Instructor

Postdoctoral Scientist

Data Science Engineer

Senior Engineer I - Data Science

Computational Chemist

Postdoctoral Researcher

Adjunct Assistant Professor

Assistant Professor

Pharmacy/Chemist/Drug store

Senior Investment Manager

Alternate Director

Investment Manager

Investment Associate

Board Observer

Acting Chief Executive Officer

Examiner, Demonstrator

Department of Surgery (Neurosurgery)

Mimecast

Outlook

Google Cloud Hosting

Greenhouse.io

Remote

Faze Medicines is a biotechnology company pioneering therapeutics based on the groundbreaking new science of biomolecular condensates. Our entire team is excited by the opportunity to harness this transformative moment in cell biology and translate discoveries in the lab to make a difference for patients. We are explorers in an emerging field, approaching this work with rigor and passion and having fun together along the way. We hope you'll join us to write the next chapter of cell biology.

Faze Medicines

Biomolecular condensates: tiny droplets with big potential | BioPharma Dive

Faze Medicines Launches With $81 Million Series A Financing to Leverage New Biology of Biomolecular Condensates to Treat Disease

Amazon AWS

Google AdSense

Mobile Friendly

We're transforming the future of healthcare by unlocking the power of what science can do for people, society and the planet. For more information, visit www.astrazeneca.com.Community Guidelines: bit.ly/2MgAcio

Global Development, Medical Science Director (Boston)

Talent Acquisition Coordinator (Temporary) Fixed Term Contract

Associate Principal Packaging Engineer

Tax Manager

Associate Director Quality Control

Associate Director, LIMS/ELN

AstraZeneca

MILTON: AstraZeneca's New AI to Predict Over 1000 Diseases Years in Advance

AstraZeneca unveils what it calls 'practice-changing' Imfinzi data in bladder cancer

AstraZeneca announces the completion of the clinical programme to support the transition of Breztri to next-generation propellant with near-zero Global Warming Potential

Amazon CloudFront

Route 53

Mailchimp Mandrill

Rackspace MailGun

KSQ Therapeutics has built an industry-leading genome-scale precision functional genomics platform, called CRISPRomics, to pinpoint therapeutic nodes that directly correlate genomic function to disease with unprecedented certainty and speed. The company is deploying CRISPRomics for novel drug development across broad therapeutic areas and is currently advancing a proprietary pipeline of tumor- and immune-focused drug candidates. KSQ was founded by thought leaders in the field of functional genomics and pioneers of CRISPR screening technologies, and the company is located in Cambridge, Massachusetts. For more information, please visit the company's website at www.ksqtx.com.

Program Team Leader

Senior Associate Scientist/Scientist, In Vivo Pharmacology

KSQ Therapeutics, Inc.

Roche agrees to develop oncology small molecule inhibitor

Japan's Ono Pharma acquires multiple oncology programmes from US-based KSQ Therapeutics

Takeda continues collaboration run to bolster global immuno-oncology footprint, says GlobalData

KSQ Therapeutics Appoints Qasim Rizvi, MB ChB., M.B.A., as Chief Executive Officer | Financial Buzz

Qasim Rizvi

NetSuite

GoDaddy Hosting

Media Temple SSL

Dicerna, a wholly owned subsidiary of Novo Nordisk, is focused on driving innovation in RNAi (ribonucleic acid interference) to selectively target and silence genes that cause or contribute to disease.  Using our proprietary GalXC™ and GalXC-Plus™ RNAi technologies, we discover and develop innovative RNAi-based therapies with the potential to treat both rare and more prevalent diseases. By silencing disease-causing genes, our GalXC platform has the potential to address conditions that are difficult to treat with other modalities. Initially focused on disease-causing genes in the liver, we have continued to innovate and are exploring new applications of our RNAi technology with GalXC-Plus, which expands on the functionality and application of our flagship liver-targeted GalXC technology to tissues and cell types outside the liver with the potential to treat diseases across multiple therapeutic areas. Our team brings together talented experts across the fields of biology, chemistry, clinical science, medicine and more. With decades of scientific and technical experience focused on RNAi technology, we have the knowledge and experience needed to discover and develop therapies for patients with serious unmet medical needs. Between our own pipeline of core discovery and clinical candidates and those developed through collaborative relationships with some of the world's leading pharmaceutical companies, we have generated more than 20 active discovery, preclinical or clinical proprietary and collaborative programs focused on rare, cardiometabolic, viral, chronic liver and complement-mediated diseases, as well as neurodegenerative diseases and pain.

Edmond Chipumuro

Director, Biological Sciences at Entact Bio

Edmond Chipumuro's Professional Contact Details

Edmond Chipumuro's Current Company Details

Entact Bio

Edmond Chipumuro's Work History and Education

Frequently Asked Questions about Edmond Chipumuro

What company does Edmond Chipumuro work for?

What is Edmond Chipumuro's role at Entact Bio?

What is Edmond Chipumuro's email address?

What is Edmond Chipumuro's business email address?

What is Edmond Chipumuro's direct mobile number?

What is Edmond Chipumuro's HQ phone number?

What industry does Edmond Chipumuro work in?

Who are Edmond Chipumuro's colleagues?

Colleagues at Entact Bio

Prospect on LinkedIn

People Search

Company Search

Erik Straub

Michael Transon

Ready to try it out?